Michael Benkowitz Sells 14,440 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 14,440 shares of United Therapeutics stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $472.13, for a total value of $6,817,557.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 9th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00.
• On Monday, February 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.95, for a total value of $10,596,375.00.
• On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $464.66, for a total value of $6,795,652.50.
• On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total transaction of $3,659,197.50.
• On Monday, January 26th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $471.91, for a total transaction of $10,617,975.00.
• On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00.
• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $487.38, for a total transaction of $3,838,117.50.
• On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $7,127,932.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total value of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $514.35, for a total value of $11,572,875.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded down $1.09 on Tuesday, hitting $473.43. 347,642 shares of the company’s stock traded hands, compared to its average volume of 327,931. The company has a fifty day moving average of $484.76 and a two-hundred day moving average of $442.24. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $519.99. The company has a market capitalization of $20.38 billion, a price-to-earnings ratio of 17.94, a price-to-earnings-growth ratio of 2.52 and a beta of 0.85.

Institutional Trading of United Therapeutics

A number of large investors have recently modified their holdings of the business. Torren Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. Entrust Financial LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth approximately $31,000. Wilmington Savings Fund Society FSB raised its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $48,000. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on UTHR. UBS Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Tuesday, February 17th. Royal Bank Of Canada raised their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. Jefferies Financial Group reissued a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.